Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Press Release Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of ShareholdersJune 27, 2024
Press Release Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDTJune 25, 2024
Press Release Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent PericarditisJune 13, 2024
Press Release Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024May 14, 2024
Press Release Cardiol Therapeutics Announces Year-End 2023 Update on OperationsApril 2, 2024
Press Release Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent PericarditisFebruary 21, 2024
Press Release Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of PericarditisFebruary 15, 2024
Press Release Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital MarketJanuary 24, 2024
Press Release Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute MyocarditisJanuary 9, 2024
View more

2023 Cardiol Therapeutics. All right reserved.